Relmada Therapeutics
Market cap $321M 106.7M shares (10-Q, Nov 10, 2026) × $3.01 close Nov 17, 2026
Most recent annual filing: 2026-03-19
- NDV-01 readout2026NDV-01 readout, 2026, material
- NDV-01 IND filingyear-end 2026NDV-01 IND filing, year-end 2026, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
sepranolone
Discontinued (2)
- esmethadone — Major Depressive Disorder · Program terminated effective July 7, 2025 following interim futility analysis in Phase 3 Reliance II study
- psilocybin — undisclosed · Program terminated effective May 12, 2025.
Capital (as filed)
- Cash
- $5.7M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $196M Sep 30, 2026
- Operating cash flow
- −$12.6M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $202M cash per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (3)
- 2026-11-13 UPDATE: Relmada Therapeutics (RLMD) - The First Cracks in a Perfect Record 🔒 Paid
- 2026-08-07 UPDATE: Relmada Therapeutics (RLMD) - The Catalyst Just Moved Right
- 2026-06-23 Relmada Therapeutics (RLMD) — Scientific Deep Dive for NDV-01 and Sepranolone 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (3 calls)
Every verdict Biotech Distilled has published on Relmada Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-06-23 Watch Relmada Therapeutics (RLMD) — Scientific Deep Dive for NDV-01 and Sepranolone NDV-01 has de-risked biology and a genuine office-based delivery advantage over INLEXZO, but pivotal-population data does not yet exist and the team's late-stage track record is poor; the year-end 2026 Cohort 2A readout is the gate to a potential upgrade.
- 2026-08-07 Watch UPDATE: Relmada Therapeutics (RLMD) - The Catalyst Just Moved Right Phase 3 initiation slipped from mid-2026 to upon IND clearance due to CMC bottleneck, pushing the first efficacy readout to 2027–2028; the thesis is stretched but not broken, and the Watch stance is maintained pending the IND filing.
- 2026-11-13 Watch UPDATE: Relmada Therapeutics (RLMD) - The First Cracks in a Perfect Record CMC appears on track for a year-end IND, but first progressions to muscle-invasive disease, a drifting BCG-unresponsive 12-month CR, a pivoting IR cohort, and contradictory funding language keep the Watch stance intact with no reason to hurry.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (25)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 28, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 2026ReleaseRelmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officervia aggregator
- Nov 16, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE ISSUED ON NOVEMBER 16, 2026
- Nov 12, 2026ReleaseRelmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updatevia aggregator→ BD updateSummary on the 8-K
- Nov 12, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 PRESS RELEASE DATED NOVEMBER 12, 2026, REGARDING CORPORATE UPDATE AND THIRD QUAR→ BD updateNDV-01's Phase 2 durability holds at 18 months — 86% of complete responders still in CR, zero Grade ≥3 AEs — while Relmada restores its "funded through 2029" guidance and signs a CMC manufacturing partner ahead of its year-end IND submission deadline.
- Nov 12, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 4, 2026ReleaseRelmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in Londonvia aggregator
- Nov 3, 2026ReleaseRelmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026via aggregator
- Sep 8, 20268-KCurrent report: other events
- Sep 1, 2026ReleaseRelmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conferencevia aggregator
- Aug 6, 2026ReleaseRelmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
- Aug 6, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AUGUST 6, 2026, REGARDING A CORPORATE UPDATE AND REPORTING IBD extracted 2 program updates from this document → RLMD pipeline
- Aug 6, 202610-QQuarterly reportBD extracted 1 program update from this document → RLMD pipeline
- Jul 28, 2026ReleaseRelmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
- Jul 28, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE ISSUED ON JULY 28, 2026
- May 28, 20268-KCurrent report: charter / bylaws / fiscal year, shareholder vote
- May 13, 2026S-3ASRAutomatic shelf registration
- May 12, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 PRESS RELEASE DATED MAY 12, 2026, REGARDING CORPORATE UPDATE AND FULL YEAR 2025
- May 12, 202610-QQuarterly report
- Apr 17, 2026DEFA14AProxy soliciting material
- Apr 17, 2026DEF 14AProxy statement
- Apr 9, 2026424B3Prospectus (resale / update)
- Apr 3, 2026S-3Shelf registration
- Mar 20, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 PRESS RELEASE DATED MARCH 19, 2026, REGARDING CORPORATE UPDATE AND FULL YEAR 202
- Mar 19, 202610-KAnnual report
- Mar 9, 20268-KCurrent report: material agreement, unregistered sale of equity, Reg FD disclosure · EX-99.1 PRESS RELEASE, DATED MARCH 9, 2026, ANNOUNCING NDV-01 12-MONTH PHASE 2 DATA
12 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Jul 29, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jun 22, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jun 18, 2026S-8Employee plan registration
- Jun 9, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 13, 2026SCHEDULE 13G/A13G amendment
- May 4, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 9, 2026EFFECTRegistration effective
- Apr 7, 2026UPLOADUPLOAD
- Apr 7, 2026CORRESPCORRESP
- Apr 6, 2026PRE 14APRE 14A